Coloplast A/S
Coloplast raises earnings expectations and increases focus on growth
Coloplast A/S 15.08.2012 12:00 --------------------------------------------------------------------------- Revenue was up 8% to DKK 8,174m in the first three quarters of the financial year 2011/2012 and the EBIT margin was 29% against 24% during the same period of last year. Organic growth by business area was 6% in Ostomy Care, 9% in Continence Care and 5% in Urology Care while growth in Wound and Skin Care was negative 2% against same period of last year. 'I'm very pleased with the way the company develops. We have delivered a solid result which means we're able to raise our earnings expectations for this financial year once again,' says CEO Lars Rasmussen. Raising full year earnings expectations In the financial year 2011/12 Coloplast continue to expect organic revenue growth of about 6% and of about 8% in DKK. The EBIT margin is raised from about 28% to about 29% at constant exchange rates and from about 29% to around 30% in DKK. Investing in growth In the third quarter Coloplast launched an updated strategy for the next 3-5 years which aims to accelerate growth. 'We believe we're able to grow more. Right now we are working to identify and asses our long-term investments in growth.' 'The future investments should maintain and strengthen our position as market leader in Europe, strengthening growth in the developed markets outside Europe (U.S., Canada, Japan and Australia) as well as providing greater expansion into new markets, including China.' Coloplast - the most customer oriented company Furthermore, in the third quarter Coloplast was ranked by patient groups world wide as the most customer oriented medical device company globally.* 'Many of our customers live with chronic diseases that are still considered taboo. We strive to help people get on with their lives by delivering high quality services and products that are safe, easy to use and don't look like medical equipment. This survey tells me that our customers appreciate what we do and that really creates a strong foundation for the future.' * Corporate reputation of the medical device industry - from the patients' perspective, Patientview, April 2012. Based on 300 patient groups from 42 countries. Coloplast no. 1 in all six categories. Read more at http://patientview.posterous.com/ and http://www.coloplast.com/about/news/patientsrankcoloplastasno1 www.coloplast.com PRESS CONTACT Ulla Lundhus Media Relations Manager +45 4911 1929 dkul@coloplast.com INVESTOR RELATIONS Ian Christensen Vice President, Investor Relations +45 4911 1301 dkisec@coloplast.com News Source: NASDAQ OMX 15.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Coloplast A/S Denmark Phone: Fax: E-mail: Internet: ISIN: DK0010309657 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden